CARM

Carisma Therapeutics Inc. (CARM) | Rumor.io

Carisma Therapeutics

CARM

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)0%

Price to earnings ratio0.03

Market capitalization242.4K

Earnings per share0.19

Dividend yield (TTM)—

Revenue (annual)19.6M

Net income (annual)-60.5M

Social

What share of all stock conversation is about CARM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Jan 17

Carisma Therapeutics' ($CARM) tech enables robotic arms to be controlled with LLMs like Claude and OpenAI.
The company's dev has 3+ years of industry experience and plans to open-source their tech for robotic control and evaluation.
The dev is active on BagsApp, listening to community feedback and testing AI models to compete in simulated physical tasks.

Generated by AI

Sentiment

Of the messages about CARM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.83% +7.71
Bearish	—	—	—	10.17% -7.71

Bullish· Sep 8

$CARM has the potential to run 50% without news and up to nicely with catalyst news.
The stock has already shown significant growth, with a 300% increase on news, and is expected to continue its upward trend.
With increasing volume and a potential catalyst on the horizon, $CARM is poised to reach new heights, possibly even surpassing $10.

Bearish· Sep 2

$CARM is experiencing massive volume, indicating potential selling pressure.
The shorts may have control, with the stock's price movement suggesting a short squeeze is unlikely.
The market's overall weakness, with major indices in the red, may be weighing on $CARM's price.

Generated by AI

Topics

Of the messages about CARM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	14.67%
Announcements	—	—	—	49.42%
Controversies	—	—	—	0.18%
Earnings	—	—	—	0%
Macro	—	—	—	16.57%
Technical Analysis	—	—	—	19.15%

Announcements· Sep 2

Carisma Therapeutics, Inc. ($CARM) announced a merger with Ocugen's subsidiary OrthoCelix, with Ocugen investing $5 million in the deal.
The combined company, OrthoCellix, Inc., will focus on advancing the NeoCart technology for regenerative cell therapies for orthopedic diseases, with existing Carisma shareholders retaining approximately 10% ownership.
Merck & Co., Inc. has acquired 1,473,240 shares of Carisma Therapeutics, Inc. ($CARM) valued at $576,921 USD as of June 30, 2025.

Controversies· Aug 19

Carisma Therapeutics, Inc. (CARM) is facing controversy over a STAT News report alleging thousands of violations of study rules and damning investigator misconduct in its clinical trial for the bladder cancer drug Vicineum.
The report claims that Sesen Bio, the company developing Vicineum, concealed patient deaths and data manipulation from investors, and that the FDA rejected the drug due to these issues.
A potential class-action lawsuit is being investigated against Sesen Bio, and the company's stock has plummeted following the report, with some analysts predicting a new trial could take up to three years to complete.

Technical Analysis· Sep 2

$CARM may be forming a bull flag, potentially breaking out in the next couple of days.
The stock has shown textbook intraday continuation, breaking out and pulling back into a tight bull flag, with VWAP still rising.
$CARM has formed a 61.8% retracement and has a weekly support level at $0.40 - $0.41.

Generated by AI

Community

Of the messages about CARM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	28.47%
Newcomers	—	100%	100%	71.53%

Regulars· Sep 2

$CARM broke out hard to $0.59 after flagging above VWAP, exhibiting textbook stair-step action with volume confirming each leg, and is being kept on radar while it holds above key intraday levels.
$CARM is showing a strong series of higher lows and volume-backed breakouts, pulling back but still above VWAP, and is being watched to see if this dip finds support for another leg or fades back into the prior range.
$CARM just ripped through $0.49 VWAP with a sharp move to $0.53, achieving 145%+ on the day and volume surging, and potential follow-through is being watched if it holds above that breakout level.

Newcomers· Oct 10

New investors are concerned about Carisma Therapeutics' (CARM) potential Nasdaq delisting and trading suspension, which has already led to a significant price drop.
Some newcomers are comparing the company's situation to other delisted stocks, such as BINI, and expressing frustration that they didn't have enough time to set up trades before the delisting announcements.
Investors are questioning the efficiency of the current market environment, citing that delisting announcements used to have a couple of weeks of setup time, but now happen within a day.

Generated by AI

Also Discussed

Investors talking about CARM also mention

#	Name	Attention
1	Axe Compute Inc.POAI	0%new
2	Cellectar Biosciences, Inc.CLRB	0%new
3	Verastem Inc.VSTM	0%0
4	Global X S&P 500 U.S. Revenue Leaders ETFEGLE	0%0
5	Royalty Pharma plc Class A Ordinary SharesRPRX	0%new
6	CERE - Cerevel Therapeutics Holdings, Inc.	——
7	Birks Group IncBGI	0%new
8	EVOK - Evoke Pharma, Inc.	——
9	Corgi All Commodities 2x Daily ETFXCOM	0%0
10	BCEI - Civitas Resources, Inc.	——

Carisma Therapeutics Inc.

Healthcare
Biotechnology

Carisma Therapeutics Inc. is a biopharmaceutical company engaged in the development of innovative cellular therapies. Its primary focus is on advancing cutting-edge treatments designed to harness the body’s innate immune system to combat cancer. By utilizing chimeric antigen receptor macrophages (CAR-M), Carisma is pioneering a new approach in the field of immunotherapy, offering potentially transformative solutions by directly targeting and eliminating malignant cells. This focus positions the company at the forefront of oncology therapeutics, with significant impacts anticipated in the biotechnology and healthcare sectors. Headquartered in the healthcare research hub of Philadelphia, Carisma Therapeutics leverages strategic partnerships and collaborations to enhance its research capabilities and expand its development pipeline. As a significant player in the ongoing evolution of cancer treatment modalities, Carisma Therapeutics contributes to the broader market dynamics through its emphasis on innovation and patient-centric solutions.

Website

Location

3675 Market Street

Philadelphia, PA, 19104

United States

Social

What share of all stock conversation is about CARM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Jan 17

Carisma Therapeutics' ($CARM) tech enables robotic arms to be controlled with LLMs like Claude and OpenAI.
The company's dev has 3+ years of industry experience and plans to open-source their tech for robotic control and evaluation.
The dev is active on BagsApp, listening to community feedback and testing AI models to compete in simulated physical tasks.

Generated by AI

Sentiment

Of the messages about CARM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.83% +7.71
Bearish	—	—	—	10.17% -7.71

Bullish· Sep 8

$CARM has the potential to run 50% without news and up to nicely with catalyst news.
The stock has already shown significant growth, with a 300% increase on news, and is expected to continue its upward trend.
With increasing volume and a potential catalyst on the horizon, $CARM is poised to reach new heights, possibly even surpassing $10.

Bearish· Sep 2

$CARM is experiencing massive volume, indicating potential selling pressure.
The shorts may have control, with the stock's price movement suggesting a short squeeze is unlikely.
The market's overall weakness, with major indices in the red, may be weighing on $CARM's price.

Generated by AI

Topics

Of the messages about CARM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	14.67%
Announcements	—	—	—	49.42%
Controversies	—	—	—	0.18%
Earnings	—	—	—	0%
Macro	—	—	—	16.57%
Technical Analysis	—	—	—	19.15%

Announcements· Sep 2

Carisma Therapeutics, Inc. ($CARM) announced a merger with Ocugen's subsidiary OrthoCelix, with Ocugen investing $5 million in the deal.
The combined company, OrthoCellix, Inc., will focus on advancing the NeoCart technology for regenerative cell therapies for orthopedic diseases, with existing Carisma shareholders retaining approximately 10% ownership.
Merck & Co., Inc. has acquired 1,473,240 shares of Carisma Therapeutics, Inc. ($CARM) valued at $576,921 USD as of June 30, 2025.

Controversies· Aug 19

Carisma Therapeutics, Inc. (CARM) is facing controversy over a STAT News report alleging thousands of violations of study rules and damning investigator misconduct in its clinical trial for the bladder cancer drug Vicineum.
The report claims that Sesen Bio, the company developing Vicineum, concealed patient deaths and data manipulation from investors, and that the FDA rejected the drug due to these issues.
A potential class-action lawsuit is being investigated against Sesen Bio, and the company's stock has plummeted following the report, with some analysts predicting a new trial could take up to three years to complete.

Technical Analysis· Sep 2

$CARM may be forming a bull flag, potentially breaking out in the next couple of days.
The stock has shown textbook intraday continuation, breaking out and pulling back into a tight bull flag, with VWAP still rising.
$CARM has formed a 61.8% retracement and has a weekly support level at $0.40 - $0.41.

Generated by AI

Community

Of the messages about CARM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	28.47%
Newcomers	—	100%	100%	71.53%

Regulars· Sep 2

$CARM broke out hard to $0.59 after flagging above VWAP, exhibiting textbook stair-step action with volume confirming each leg, and is being kept on radar while it holds above key intraday levels.
$CARM is showing a strong series of higher lows and volume-backed breakouts, pulling back but still above VWAP, and is being watched to see if this dip finds support for another leg or fades back into the prior range.
$CARM just ripped through $0.49 VWAP with a sharp move to $0.53, achieving 145%+ on the day and volume surging, and potential follow-through is being watched if it holds above that breakout level.

Newcomers· Oct 10

New investors are concerned about Carisma Therapeutics' (CARM) potential Nasdaq delisting and trading suspension, which has already led to a significant price drop.
Some newcomers are comparing the company's situation to other delisted stocks, such as BINI, and expressing frustration that they didn't have enough time to set up trades before the delisting announcements.
Investors are questioning the efficiency of the current market environment, citing that delisting announcements used to have a couple of weeks of setup time, but now happen within a day.

Generated by AI

Carisma Therapeutics

Social

Jan 17

Sentiment

Bullish· Sep 8

Bearish· Sep 2

Topics

Announcements· Sep 2

Controversies· Aug 19

Technical Analysis· Sep 2

Community

Regulars· Sep 2

Newcomers· Oct 10

Also Discussed

Carisma Therapeutics Inc.

Company Information

Location

Also Discussed

Social

Jan 17

Sentiment

Bullish· Sep 8

Bearish· Sep 2

Topics

Announcements· Sep 2

Controversies· Aug 19

Technical Analysis· Sep 2

Community

Regulars· Sep 2

Newcomers· Oct 10